Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model
Page 1 of 1
Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model
Martins Metelo A, Noonan HR, Xiang L, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O. Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest. 2015 Apr 13. pii: 73665. doi: 10.1172/JCI73665. [Epub ahead of print]
Similar topics
» Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
» Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease)
» Distinct phenotypes in zebrafish models of human startle disease
» Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo
» RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1
» Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease)
» Distinct phenotypes in zebrafish models of human startle disease
» Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo
» RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum